- Details
- Joining Alicia Morgans is Neal Shore to further highlight his team's presentation at this year's GU ASCO 2022 Annual Meeting focusing on evaluating the feasibility of instituting a hereditary cancer risk assessment (HCRA) protocol in their urological practice for prostate cancer patients. The results found were encouraging for the incorporation of recommended genomic screenings in community urolog...
|
- Details
- Drs Oliver Sartor and Kendra Harris join Phillip Koo to discuss the clinical implications and integration of Pluvicto™ into clinical practice and offer guidance to clinicians looking to implement this therapy in their clinics. Pluvicto™ (177Lu-PSMA-617) is the first FDA-approved targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer. Biographies: A. Olive...
|
- Details
- Fred Saad joins Alicia Morgans to discuss the results of the PROpel phase 3 trial of olaparib and abiraterone versus placebo and abiraterone as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Fred Saad, MD, FRCS, Professor and Chief of Urology, Director of GU Oncology, Raymond Garneau Chair in Prostate Cancer, University of Montreal Hospit...
|
- Details
- Kara Maxwell and Alicia Morgans discuss DNA repair defect alterations in patients with localized prostate cancer. Dr. Maxwell highlights DNA repair in conjunction with prostate cancer, as well as the Penn Medicine BioBank. The conversation concludes with a discussion on the future of prostate cancer genomics. Biographies: Kara N. Maxwell, MD, Ph.D., Assistant Professor of Medicine and Genetics, Un...
|
- Details
- In this LUGPA CME presentation, Dr Emmanuel Antonarakis discussed genomic profiling, germline, and somatic testing in the landscape of prostate cancer. He discusses what are germline mutations, what are somatic mutations, how common they are in prostate cancer as well as who should be tested for these mutations. Dr. Antonarakis guides the views through a genomics report, a next-generation sequenci...
|
- Details
- Alicia Morgans, MD, MPH, is joined by Michael Morris, MD, to discuss the phase III VISION trial results and the practice-changing implications when lutetium-177-PSMA-617 is FDA approved. The VISION trial evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined standard of care with...
|
- Details
- Detection and Localization of Prostate Cancer: Case-based Scan Reading Review PSMA Molecular Targeted Radiation Therapy - Part Three of Three- Scan Reader Training and Discussions Presenter: Andrei Iagaru. Independent Medical Education Initiative Supported by Novartis Pharmaceutical Corporation Biographies: Program Presenter: Andrei H. Iagaru, MD, FACNM, Professor of Radiology - Nuclear Medicine,...
|
- Details
- Detection and Localization of Prostate Cancer: Case-based Scan Reading Review Demonstrating PSMA Molecular Diagnostic Imaging with18F-DCFPyL or 68Ga-PSMA11 for Prostate Cancer Staging and Clinical Case Discussions - Part Two of Three in Scan Reader Training and Discussions. Independent Medical Education Initiative Supported by Novartis Pharmaceutical Company Biographies: Program Presenter: Andrei...
|
- Details
- Detection and Localization of Prostate Cancer: Case-based Scan Reading Review 18F-Fluciclovine Cases - Part One of Three - Scan Reader Training and Discussions Presenter: Andrei Iagaru. Independent Medical Education Initiative Supported by Advanced Accelerator Applications, A Novartis Company Biographies: Program Presenter: Andrei H. Iagaru, MD, FACNM, Professor of Radiology - Nuclear Medicine, Ch...
|
- Details
- Charles Ryan, MD, is joined by Veda Giri, MD, Patrick Pilié, MD, and Arpit Rao, MD, MBBS, for a roundtable discussion on DNA repair and Poly (ADP-ribose) polymerase (PARP) inhibitor therapy in prostate cancer. To begin, Dr. Giri discusses the need for widespread genetic testing in the clinic today. Following the May 2020 United States Federal Drug Administration (FDA) approvals of PARP inhibitors...
|
